JP2011507498A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507498A5
JP2011507498A5 JP2010538889A JP2010538889A JP2011507498A5 JP 2011507498 A5 JP2011507498 A5 JP 2011507498A5 JP 2010538889 A JP2010538889 A JP 2010538889A JP 2010538889 A JP2010538889 A JP 2010538889A JP 2011507498 A5 JP2011507498 A5 JP 2011507498A5
Authority
JP
Japan
Prior art keywords
fusion protein
nucleic acid
aggrecanase
tgfβ
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010538889A
Other languages
English (en)
Japanese (ja)
Other versions
JP5683272B2 (ja
JP2011507498A (ja
Filing date
Publication date
Priority claimed from GBGB0724556.6A external-priority patent/GB0724556D0/en
Application filed filed Critical
Publication of JP2011507498A publication Critical patent/JP2011507498A/ja
Publication of JP2011507498A5 publication Critical patent/JP2011507498A5/ja
Application granted granted Critical
Publication of JP5683272B2 publication Critical patent/JP5683272B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010538889A 2007-12-17 2008-12-17 アグリカナーゼ感受性切断部位を有する潜在関連タンパク質構築物 Expired - Fee Related JP5683272B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0724556.6A GB0724556D0 (en) 2007-12-17 2007-12-17 LAtency associated protein construct with aggrecanase sensitive cleavage site
GB0724556.6 2007-12-17
PCT/GB2008/004167 WO2009077755A2 (en) 2007-12-17 2008-12-17 Latency associated protein construct with aggrecanase sensitive cleavage site

Publications (3)

Publication Number Publication Date
JP2011507498A JP2011507498A (ja) 2011-03-10
JP2011507498A5 true JP2011507498A5 (enExample) 2013-02-14
JP5683272B2 JP5683272B2 (ja) 2015-03-11

Family

ID=39048208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538889A Expired - Fee Related JP5683272B2 (ja) 2007-12-17 2008-12-17 アグリカナーゼ感受性切断部位を有する潜在関連タンパク質構築物

Country Status (7)

Country Link
US (1) US8357515B2 (enExample)
EP (1) EP2262540B1 (enExample)
JP (1) JP5683272B2 (enExample)
DK (1) DK2262540T3 (enExample)
ES (1) ES2552018T3 (enExample)
GB (1) GB0724556D0 (enExample)
WO (1) WO2009077755A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895420B2 (en) 2013-06-05 2018-02-20 B.G. Negev Technologies And Applications Ltd., At Ben Gurion University IL-1beta propeptide and IL-1Ra chimera and methods of using the same
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
ES2780274A1 (es) 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103002A (en) 1977-02-08 1978-07-25 Board Of Regents, University Of Florida Bioglass coated A1203 ceramics
US4234972A (en) 1978-06-21 1980-11-25 Board Of Regents, State Of Florida Bioglass coated metal substrate
US4725234A (en) 1985-08-15 1988-02-16 Ethridge Edwin C Alveolar bone grafting process with controlled surface active ceramics
DE3907663A1 (de) 1989-03-09 1990-09-13 Espe Stiftung Knochenersatzteil aus glasionomerzement
FR2651439B1 (fr) 1989-09-06 1994-09-23 Fbfc International Sa Nv Materiau bioreactif pour prothese ou implants composites.
US5074916A (en) 1990-05-18 1991-12-24 Geltech, Inc. Alkali-free bioactive sol-gel compositions
JP2807752B2 (ja) 1993-05-17 1998-10-08 ティーディーケイ株式会社 結晶化ガラス材
GB9319971D0 (en) 1993-09-28 1993-11-17 Cookson Group Plc Cobalt glass compositions for coatings
US5679338A (en) * 1994-05-12 1997-10-21 Osteoarthritis Science, Inc. Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues
FI101129B (sv) 1995-01-13 1998-04-30 Vivoxid Oy Nya bioaktiva glas och deras användning
US6224913B1 (en) 1996-05-09 2001-05-01 The Trustees Of The University Of Pennsylvania Conditioning of bioactive glass surfaces in protein containing solutions
FR2749759B1 (fr) 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
AU4723297A (en) 1996-10-23 1998-05-15 Sunstar Inc. Oral preparations containing biologically active crystallized glass
DE69806714T2 (de) 1997-03-13 2003-04-03 Saint-Gobain Glass France, Courbevoie Kalknatron-silikatglaszusammensetzungen und deren anwendungen
US6482444B1 (en) 1999-06-14 2002-11-19 Imperial College Innovations Silver-containing, sol/gel derived bioglass compositions
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
DE10111449A1 (de) 2001-03-09 2002-09-26 Schott Glas Verwendung von bioaktivem Glas in Zahnfüllmaterial
US20060233887A1 (en) 2003-02-14 2006-10-19 The North West London Hospitals N H S Trust Bioactive material for use in stimulating vascularization
DE112004000094A5 (de) 2003-02-25 2008-04-03 Schott Ag Antimikrobiell wirkendes Borosilicatglas
US6905723B2 (en) 2003-05-30 2005-06-14 Depuy Products, Inc. Strontium-substituted apatite coating
CN1292804C (zh) 2004-03-08 2007-01-03 西安交通大学 含锶纳米磷酸钙生物活性骨水泥的制备工艺
DE102004026432A1 (de) 2004-05-29 2005-12-22 Schott Ag Glaszusammensetzungen als antimikrobieller Zusatz für Dentalmaterialien und deren Verwendung
BRPI0517815B1 (pt) 2004-11-12 2016-08-23 Dentsply Detrey Gmbh composição vítrea de aluminossilicato, seu uso, carga vítrea em partículas, composição de cimento dentário de ionômero de vidro e processo para sua preparação
WO2007020613A1 (en) 2005-08-12 2007-02-22 University Of Limerick A synthetic graft having a glass network
DE102006036019A1 (de) 2006-08-02 2008-02-07 Pemeas Gmbh Membran-Elektroden-Einheit und Brennstoffzellen mit erhöhter Leistung
US20080182920A1 (en) 2007-01-26 2008-07-31 Mark Robert Towler Bone cement

Similar Documents

Publication Publication Date Title
US12173060B2 (en) Compositions and methods of use for treating metabolic disorders
RU2011138951A (ru) Пропротеины и способы их применения
JP2004504032A5 (enExample)
JP2011507498A5 (enExample)
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
JP2004520031A5 (enExample)
CA2795168A1 (en) Factor xii inhibitors for treating interstitial lung disease
JP2018512124A5 (enExample)
JP2008521426A5 (enExample)
TW200526780A (en) TNF antagonists and TNF inhibitors comprising the same as the active ingredient
US20240270797A1 (en) Coronavirus neutralizing compositions and associated methods
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
JP2013529178A5 (enExample)
JP2017526625A5 (enExample)
JPWO2020181145A5 (enExample)
CN111094319B (zh) 乙酰胆碱受体结合肽
JP2009520480A5 (enExample)
WO2006018450A3 (en) Pharmaceutically active insulin receptor-modulating molecules
WO2025096770A1 (en) Multi-chain chimeric polypeptides and uses thereof
WO2023196916A1 (en) Methods of treating of hidradenitis suppurativa
García-Escobar Letter regarding: Another strategy for off-target ACE2
JP2001269184A5 (enExample)
JP2024501770A (ja) シアリダーゼ－ｐｄ－１－抗体融合タンパク質及びその使用方法
HK40035218A (en) Compositions and methods of use for treating metabolic disorders
WO2024229369A3 (en) Antibodies targeting human leukocyte antigen cathepsin g peptide complex